3970-05-6

Usage

Uses

Used in Pharmaceutical Production:
2-(AMINOMETHYL)-4-CHLOROPHENOL is used as an intermediate in the production of pharmaceuticals for its ability to contribute to the development of various medicinal compounds.
Used as a Disinfectant and Antimicrobial Agent:
2-(AMINOMETHYL)-4-CHLOROPHENOL is used as a disinfectant and antimicrobial agent due to its antiseptic and antibacterial properties, which help in killing or inhibiting the growth of microorganisms.
Used in Personal Care Products:
2-(AMINOMETHYL)-4-CHLOROPHENOL is used in the formulation of personal care products such as hand sanitizers and skincare products, where its antimicrobial properties contribute to maintaining hygiene and preventing the spread of infections.
Used in Chemical Synthesis:
2-(AMINOMETHYL)-4-CHLOROPHENOL is used in the synthesis of other chemicals, highlighting its versatility as a building block in various chemical processes.
It is important to handle 2-(AMINOMETHYL)-4-CHLOROPHENOL with care and in accordance with safety guidelines due to its potential health hazards.

InChI:InChI=1/C7H8ClNO/c8-6-1-2-7(10)5(3-6)4-9/h1-3,10H,4,9H2

Upstream product

• 87974-49-0 5-chloro-2-hydroxy-benzaldehyde oxime 
• 7120-43-6 5-chlorosalicylamide 
• 635-93-8 5-chlorosalicyclaldehyde 
• 2420-26-0 4-chlorosalicylaldehyde 

Downstream Products

• 75551-87-0 2-Aminomethyl-4-chloro-6-iodo-phenol; hydrochloride 
• 195517-88-5 (5-chloro-2-hydroxybenzyl)carbamic acid tert-butyl ester 
• 331729-64-7 2-(5-chloro-2-hydroxy-benzyl)isoindole-1,3-dione 
• 871266-70-5 C₂₀H₁₉ClI₃N₃O₆ 
• 331729-40-9 5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzylamine 
• 331729-41-0 2-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzyl]isoindole-1,3-dione 
• 331728-88-2 3-azido-5-{6-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy) benzylamino]purin-9-yl}-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide 
• 331727-55-0 CP-608039 
• 525605-80-5 C₁₂H₁₀ClN₅O 
• 862540-76-9 2-[3-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]-N-(5-chloro-2-hydroxybenzyl)acetamide 
• 1448338-28-0 4-chloro-2-[(2-chloro-9-cyclopentyl-9H-purin-6-ylamino)methyl]phenol 
• 1427518-62-4 4-chloro-2-[(2-chloro-9-isopropyl-9H-purin-6-ylamino)-methyl]-phenol 
• 940870-89-3 1-(2-(2-morpholinopyrimidin-4-yloxy)-5-chlorobenzyl)-3-(3-t-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea 
• 940870-88-2 1-(2-(2-chloropyrimidin-4-yloxy)-5-chlorobenzyl)-3-(3-t-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea 

Relevant academic research and scientific papers

Characterization of scavengers of γ-ketoaldehydes that do not inhibit prostaglandin biosynthesis

Expression of cyclooxygenase-2 (COX-2) is associated with the development of many pathologic conditions. The product of COX-2, prostaglandin H2 (PGH2), can spontaneously rearrange to form reactive γ-ketoaldehydes called levuglandins (LGs). This γ-ketoaldehyde structure confers a high degree of reactivity on the LGs, which rapidly form covalent adducts with primary amines of protein residues. Formation of LG adducts of proteins has been demonstrated in pathologic conditions (e.g., increased levels in the hippocampus in Alzheimer's disease) and during physiologic function (platelet activation). On the basis of knowledge that lipid modification of proteins is known to cause their translocation and to alter their function, we hypothesize that modification of proteins by LG could have functional consequences. Testing this hypothesis requires an experimental approach that discriminates between the effects of protein modification by LG and the effects of cyclooxygenase-derived prostanoids acting through their G-protein coupled receptors. To achieve this goal, we have synthesized and evaluated a series of scavengers that react with LG with a potency more than 2 orders of magnitude greater than that with the ε-amine of lysine. A subset of these scavengers are shown to block the formation of LG adducts of proteins in cells without inhibiting the catalytic activity of the cyclooxygenases. Ten of these selective scavengers did not produce cytotoxicity. These results demonstrate that small molecules can scavenge LGs in cells without interfering with the formation of prostaglandins. They also provide a working hypothesis for the development of pharmacologic agents that could be used in experimental animals in vivo to assess the pathophysiological contribution of levuglandins in diseases associated with cyclooxygenase up-regulation.

Cytokinin receptor antagonists derived from 6-benzylaminopurine

Recently we reported 6-(2-hydroxy-3-methylbenzylamino)purine (PI-55) as the first molecule to antagonize cytokinin activity at the receptor level. Here we report the synthesis and in vitro biological testing of eleven BAP derivatives substituted in the be

PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS

Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.

Anticoagulant contrast media

The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists

A series of ring-constrained (N)-methanocarba-5′-uronamide 2,N 6-disubstituted adenine nucleosides have been synthesized via Mitsunobu condensation of the nucleobase precursor with a pseudosugar ring containing a 5′-ester functionality. Following appropriate functionalization of the adenine ring, the ester group was converted to the 5′-N-methylamide. The compounds, mainly 2-chloro-substituted derivatives, were tested in both binding and functional assays at human adenosine receptors (ARs), and many were found to be highly potent and selective A3-AR agonists. Selected compounds were compared in binding to the rat A3AR to assess their viability for testing in rat disease models. The N 6-(3-chlorobenzyl) and N6-(3-bromobenzyl) analogues displayed Ki values at the human A3AR of 0.29 and 0.38 nM, respectively. Other subnanomolar affinities were observed for the following N6 derivatives: 2,5-dichlorobenzyl, 5-iodo-2-methoxybenzyl, trans-2-phenyl-1-cyclopropyl, and 2,2-diphenylethyl. Selectivity for the human A3AR in comparison to the A1AR was the following (fold): the N6-(2,2-diphenylethyl) analogue 34 (1900), the N 6-(2,5-dimethoxybenzyl) analogue 26 (1200), the N6-(2,5- dichlorobenzyl) and N6-(2-phenyl-1-cyclopropyl) analogues 20 and 33 (1000), and the N6-(3-substituted benzyl) analogues 17, 18, 28, and 29 (700-900). Typically, even greater selectivity ratios were obtained in comparison with the A2A and A2BARs. The (N)-methanocarba-5′-uronamide analogues were full agonists at the A 3AR, as indicated by the inhibition of forskolin-stimluated adenylate cyclase at a concentration of 10 μM. The N6-(2,2-diphenylethyl) derivative was an A3AR agonist in the (N)-methanocarba-5′- uronamide series, although it was an antagonist in the ribose series. Thus, many of the previously known groups that enhance A3AR affinity in the 9-riboside series, including those that reduce intrinsic efficacy, may be adapted to the (N)-methanocarba nucleoside series of full agonists.

SUBSTITUTED PYRIMIDINES

The invention relates to novel substituted pyrimidines of formula (I), in which R1, R2, R3, R4, Q, X and n have the meanings as cited in the description. The invention also relates to a method and intermediate products for producing these pyrimidines, and to the use thereof as plant control agents, particularly as herbicides.

PYRIDINONE THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: STR1 for example: STR2

2-(Aminomethyl)phenols, a new class of saluretic agents. I. Effect of nuclear substitution

A series of 2-(aminomethyl)phenols was synthesized and tested in rats and dogs for saluretic and diuretic activity. A number of these compounds exhibit a high order of activity on iv or po administration. The most active compounds belong to a subseries of 4-alkyl-6-halo derivatives of which 2,2(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl, is the most active. Compound 2 also possesses significant antihypertensive activity, an adjunctive pharmacological parameter which distinguishes 2 from the other compounds prepared in this series. In addition, 2 displays both topical saluretic and antiinflammatory activities.